Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

ConferenceASC36_35FDCPositive

AI Analysis

Summary

Ascletis Pharma presented preclinical data for ASC36_35FDC demonstrating potential for once-monthly to once-quarterly dosing with robust weight loss in animal studies at the EASD 2026 Annual Meeting.

Importance:4/10

Sentiment:

0.60

preclinical dataweight losslong-acting formulationEASD 2026ASC36_35FDC

Related Companies

$1672

Read the original article

Published by PR Newswire Pharma on October 2, 2026 9:00 AM

Read Original